Answers are grounded in this paper and cite their sources.
Background. High-dose vitamin C has been promoted as a cancer treatment since the 1970s. Oral and intravenous (IV) dosing produce very different blood levels, and the two routes have often been discussed as if they were one intervention. A 2025 meta-analysis pooled randomised trials with cohort studies, used a median survival ratio, and concluded that IV vitamin C had moderate-certainty evidence and should be considered as standard of care. This review re-examines that claim with randomised evidence kept separate from non-randomised evidence and each cancer type judged on its own data. Main results. 18 studies met the inclusion criteria: 10 randomised trials, 1 comparative study whose randomisation is not described, and 7 non-randomised comparative studies. Four IV trials reported an overall survival hazard ratio, one per cancer type. Colorectal cancer (Wang 2022, phase III, n=442): HR 1.04 (95% CI 0.81 to 1.33), moderate certainty. Pancreatic cancer (Bodeker 2024, phase II, n=34 treated, stopped early): HR 0.46 (90% CI 0.23 to 0.92), very low certainty. Non-small cell lung cancer (Ou 2020, vitamin C always given with electro-hyperthermia): HR 0.33 (as printed), very low certainty for vitamin C itself. Prostate cancer (Paller 2024, stopped for futility): HR 1.98 (95% CI 0.85 to 4.58), low certainty. The all-cancer IV pool gave HR 0.73 with I-squared 87.5% and a 95% prediction interval of 0.02 to 25.07, so it does not describe a common effect. Excluding the hyperthermia trial moved the pool to HR 0.99. A sensitivity pool of the two trials at low risk of bias gave HR 1.26. Progression-free survival pooled to HR 0.86 (Hartung-Knapp 95% CI 0.49 to 1.53), low certainty. Oral vitamin C trials from 1979 and 1985 reported no survival advantage. Authors' conclusions. The randomised record does not support the 2025 claim of moderate-certainty benefit. The largest trial found no significant survival benefit. One small pancreatic trial found a large benefit and was stopped early, which tends to flatter a result. High-dose IV vitamin C remains investigational. The US Food and Drug Administration has not approved it as a treatment for cancer. Five databases (Embase, Scopus, Web of Science, CENTRAL, CINAHL) were not searched; this limit is stated in the manuscript.
No takes yet. Share an insight, caveat, or question.
Raphael Malikian (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: